source
- Cytospire hauls in $83M for a new type of T cell engagerThe British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.BioPharma Dive · 2mo ago↗ source
- STAT+: Johnson & Johnson advances IBD therapy, despite trial missA closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.STAT · 2mo ago↗ source
- STAT+: French regulator fines Novo and Lilly over weight loss ad campaignsFrance's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.STAT · 2mo ago↗ source